Published in PLoS One on August 15, 2013
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 3.10
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Catalytic antibodies. Science (1986) 2.41
Selective chemical catalysis by an antibody. Science (1986) 2.19
Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant (2002) 2.01
DNA hydrolyzing autoantibodies. Science (1992) 1.88
Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science (1989) 1.71
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol (2004) 1.68
The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med (2002) 1.62
Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant (2007) 1.60
Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood (2010) 1.53
Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol (1994) 1.45
Hypothesis. Auto-antibodies and immunological theories: an analytical review. Clin Immunol Immunopathol (1975) 1.38
What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 1.31
Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A (2005) 1.28
Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell (2001) 1.26
Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant (2004) 1.09
Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol (1998) 1.09
Ontogeny of proteolytic immunity: IgM serine proteases. J Biol Chem (2004) 1.07
Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J Biol Chem (1995) 1.07
Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation (2010) 1.03
Catalytic activity of anti-thyroglobulin antibodies. J Immunol (1995) 1.02
Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem (2003) 1.01
High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A (2005) 0.99
Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med (1999) 0.96
Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl Immunol (2011) 0.96
Phosphonate ester probes for proteolytic antibodies. J Biol Chem (2001) 0.92
Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation (2006) 0.91
Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood (2002) 0.90
Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol (1991) 0.89
Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies. Mol Biotechnol (2007) 0.88
Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J Immunol (2008) 0.86
Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde. Bioessays (2009) 0.86
Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcgammaRIIb. J Allergy Clin Immunol (2002) 0.85
Functional mimicry: elicitation of a monoclonal anti-idiotypic antibody hydrolizing beta-lactams. FASEB J (1998) 0.85
Superantibody activities: new players in innate and adaptive immune responses. Immunol Today (1998) 0.84
Secretory immunoglobulin A from healthy human mothers' milk catalyzes nucleic acid hydrolysis. Appl Biochem Biotechnol (2000) 0.83
Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol (1993) 0.82
Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Lett (2009) 0.81
Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol (2008) 0.80
Feedback inhibition of B cell differentiation by monomeric immunoglobulin. Int Rev Immunol (1989) 0.79
A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients. Clin Transpl (2011) 0.78
Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G. Blood Coagul Fibrinolysis (2006) 0.76
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med (2013) 3.41
Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 2.63
PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest (2012) 2.61
Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 2.56
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis (2003) 2.21
Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant (2003) 2.21
NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int (2004) 2.08
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol (2012) 2.03
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int (2009) 2.01
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol (2003) 1.93
High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol (2007) 1.90
Kidney transplant in black recipients: are African Europeans different from African Americans? Am J Transplant (2005) 1.88
Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis (2012) 1.84
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 1.83
Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2009) 1.75
Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int (2011) 1.73
Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int (2008) 1.71
Multivariate analysis of donor risk factors for graft survival in kidney transplantation. Transplantation (2003) 1.69
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Very long-term follow-up of living kidney donors. Transpl Int (2012) 1.61
Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant (2009) 1.58
Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 1.57
Transition towards antigen-binding promiscuity of a monospecific antibody. Mol Immunol (2006) 1.54
Autophagy protects renal tubular cells against cyclosporine toxicity. Autophagy (2008) 1.53
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
Kidney function following nephrectomy: similitude and discrepancies between kidney cancer and living donation. Urol Oncol (2010) 1.53
Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood (2010) 1.53
Determination of lowest possible creatinine in living-donor kidney renal transplant recipients based on donor kidney function. Transplantation (2008) 1.50
To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation (2007) 1.49
Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant (2004) 1.48
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 1.48
Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy. Transplantation (2011) 1.47
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood (2002) 1.46
Sirolimus therapy may cause cardiac tamponade. Transpl Int (2012) 1.43
Clinical and immunological features of very long-term survivors with a single renal transplant. Transpl Int (2012) 1.42
Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation (2010) 1.41
Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int (2011) 1.39
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation (2005) 1.39
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood (2009) 1.37
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant (2003) 1.34
The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol (2013) 1.34
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood (2004) 1.30
Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J Am Soc Nephrol (2010) 1.30
Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol (2008) 1.29
Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A (2005) 1.28
Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol (2010) 1.28
Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol (2007) 1.25
Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A (2004) 1.24
Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol (2007) 1.23
mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) (2008) 1.22
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol (2008) 1.21
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf (2012) 1.17
Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci (2009) 1.16
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci (2004) 1.13
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Replacement kidney lipomatosis after renal transplantation. Transplantation (2005) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant (2009) 1.11
Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation (2004) 1.10
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther (2004) 1.10
B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation (2008) 1.09
Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris. PLoS One (2013) 1.09
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol (2011) 1.07
Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells. J Am Coll Cardiol (2007) 1.06
Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation (2011) 1.06
Improving estimates of event incidence over time in populations exposed to other events: application to three large databases. J Clin Epidemiol (2003) 1.06
Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood (2008) 1.05
Interferon-α inhibition by intravenous immunoglobulin is independent of modulation of the plasmacytoid dendritic cell population in the circulation: comment on the article by Wiedeman et al. Arthritis Rheumatol (2014) 1.05
Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant (2005) 1.04
Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood (2006) 1.03
Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS (2009) 1.03
A clinical scoring system highly predictive of long-term kidney graft survival. Kidney Int (2010) 1.03
Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS One (2012) 1.03
Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation (2010) 1.03
Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine. Transplantation (2007) 1.02
Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci (2007) 1.01
The antiinflammatory IgG. N Engl J Med (2008) 1.00
Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol (2010) 1.00
Kaposi sarcoma in transplantation. Transplant Rev (Orlando) (2008) 1.00
Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int (2005) 0.99
Glomerular collapse associated with subtotal renal infarction in kidney transplant recipients with multiple renal arteries. Am J Kidney Dis (2009) 0.99
Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem (2005) 0.98
Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant (2008) 0.98
Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol (2005) 0.98
Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol (2013) 0.97
Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discov Today (2011) 0.97